![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NUP210 |
Gene summary for NUP210 |
![]() |
Gene information | Species | Human | Gene symbol | NUP210 | Gene ID | 23225 |
Gene name | nucleoporin 210 | |
Gene Alias | GP210 | |
Cytomap | 3p25.1 | |
Gene Type | protein-coding | GO ID | GO:0006403 | UniProtAcc | Q8TEM1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23225 | NUP210 | CCI_2 | Human | Cervix | CC | 6.15e-11 | 7.45e-01 | 0.5249 |
23225 | NUP210 | CCI_3 | Human | Cervix | CC | 8.56e-06 | 4.49e-01 | 0.516 |
23225 | NUP210 | CCII_1 | Human | Cervix | CC | 1.54e-04 | 3.15e-01 | 0.3249 |
23225 | NUP210 | T1 | Human | Cervix | CC | 4.46e-08 | 3.37e-01 | 0.0918 |
23225 | NUP210 | NAFLD1 | Human | Liver | NAFLD | 6.47e-04 | 3.84e-01 | -0.04 |
23225 | NUP210 | HCC1_Meng | Human | Liver | HCC | 7.27e-51 | 9.26e-02 | 0.0246 |
23225 | NUP210 | HCC2_Meng | Human | Liver | HCC | 1.42e-02 | -3.49e-02 | 0.0107 |
23225 | NUP210 | S014 | Human | Liver | HCC | 1.12e-17 | 7.86e-01 | 0.2254 |
23225 | NUP210 | S015 | Human | Liver | HCC | 2.29e-15 | 7.57e-01 | 0.2375 |
23225 | NUP210 | S016 | Human | Liver | HCC | 3.22e-18 | 6.83e-01 | 0.2243 |
23225 | NUP210 | S027 | Human | Liver | HCC | 5.38e-19 | 1.20e+00 | 0.2446 |
23225 | NUP210 | S028 | Human | Liver | HCC | 1.06e-39 | 1.55e+00 | 0.2503 |
23225 | NUP210 | S029 | Human | Liver | HCC | 3.67e-35 | 1.53e+00 | 0.2581 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00512368 | Cervix | CC | establishment of RNA localization | 39/2311 | 166/18723 | 4.76e-05 | 7.25e-04 | 39 |
GO:00506578 | Cervix | CC | nucleic acid transport | 38/2311 | 163/18723 | 7.06e-05 | 9.85e-04 | 38 |
GO:00506588 | Cervix | CC | RNA transport | 38/2311 | 163/18723 | 7.06e-05 | 9.85e-04 | 38 |
GO:000640310 | Cervix | CC | RNA localization | 43/2311 | 201/18723 | 2.00e-04 | 2.29e-03 | 43 |
GO:00510284 | Cervix | CC | mRNA transport | 31/2311 | 130/18723 | 2.05e-04 | 2.33e-03 | 31 |
GO:00159318 | Cervix | CC | nucleobase-containing compound transport | 43/2311 | 222/18723 | 1.72e-03 | 1.30e-02 | 43 |
GO:00512366 | Liver | NAFLD | establishment of RNA localization | 28/1882 | 166/18723 | 4.35e-03 | 3.57e-02 | 28 |
GO:00064037 | Liver | NAFLD | RNA localization | 32/1882 | 201/18723 | 5.96e-03 | 4.48e-02 | 32 |
GO:000640321 | Liver | HCC | RNA localization | 151/7958 | 201/18723 | 3.72e-21 | 5.89e-19 | 151 |
GO:005123621 | Liver | HCC | establishment of RNA localization | 121/7958 | 166/18723 | 1.61e-15 | 1.19e-13 | 121 |
GO:005065711 | Liver | HCC | nucleic acid transport | 118/7958 | 163/18723 | 8.30e-15 | 5.60e-13 | 118 |
GO:005065811 | Liver | HCC | RNA transport | 118/7958 | 163/18723 | 8.30e-15 | 5.60e-13 | 118 |
GO:001593111 | Liver | HCC | nucleobase-containing compound transport | 150/7958 | 222/18723 | 3.17e-14 | 2.03e-12 | 150 |
GO:005102811 | Liver | HCC | mRNA transport | 97/7958 | 130/18723 | 9.00e-14 | 5.23e-12 | 97 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501418 | Cervix | CC | Amyotrophic lateral sclerosis | 103/1267 | 364/8465 | 1.79e-11 | 4.47e-10 | 2.64e-10 | 103 |
hsa0501419 | Cervix | CC | Amyotrophic lateral sclerosis | 103/1267 | 364/8465 | 1.79e-11 | 4.47e-10 | 2.64e-10 | 103 |
hsa0501422 | Liver | HCC | Amyotrophic lateral sclerosis | 252/4020 | 364/8465 | 8.85e-18 | 7.41e-16 | 4.12e-16 | 252 |
hsa03013 | Liver | HCC | Nucleocytoplasmic transport | 81/4020 | 108/8465 | 4.28e-09 | 6.83e-08 | 3.80e-08 | 81 |
hsa0501432 | Liver | HCC | Amyotrophic lateral sclerosis | 252/4020 | 364/8465 | 8.85e-18 | 7.41e-16 | 4.12e-16 | 252 |
hsa030131 | Liver | HCC | Nucleocytoplasmic transport | 81/4020 | 108/8465 | 4.28e-09 | 6.83e-08 | 3.80e-08 | 81 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NUP210 | SNV | Missense_Mutation | novel | c.292N>A | p.Ala98Thr | p.A98T | Q8TEM1 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-B5-A5OC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD |
NUP210 | SNV | Missense_Mutation | novel | c.3478N>C | p.Val1160Leu | p.V1160L | Q8TEM1 | protein_coding | deleterious(0.01) | possibly_damaging(0.496) | TCGA-BG-A3EW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
NUP210 | SNV | Missense_Mutation | rs561241593 | c.3673C>T | p.Arg1225Trp | p.R1225W | Q8TEM1 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-BK-A0C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NUP210 | SNV | Missense_Mutation | rs141201901 | c.1160N>A | p.Arg387Gln | p.R387Q | Q8TEM1 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NUP210 | SNV | Missense_Mutation | c.892C>T | p.Arg298Trp | p.R298W | Q8TEM1 | protein_coding | deleterious(0.03) | benign(0) | TCGA-D1-A17T-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
NUP210 | SNV | Missense_Mutation | rs375414642 | c.5446N>A | p.Ala1816Thr | p.A1816T | Q8TEM1 | protein_coding | deleterious(0.03) | probably_damaging(0.997) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
NUP210 | SNV | Missense_Mutation | rs779161656 | c.4850N>T | p.Pro1617Leu | p.P1617L | Q8TEM1 | protein_coding | deleterious(0) | benign(0.015) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
NUP210 | SNV | Missense_Mutation | novel | c.4148N>T | p.Pro1383Leu | p.P1383L | Q8TEM1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
NUP210 | SNV | Missense_Mutation | novel | c.4028N>A | p.Gly1343Glu | p.G1343E | Q8TEM1 | protein_coding | deleterious(0) | possibly_damaging(0.905) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
NUP210 | SNV | Missense_Mutation | novel | c.3387N>T | p.Gln1129His | p.Q1129H | Q8TEM1 | protein_coding | tolerated(0.1) | benign(0.183) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |